Opendata, web and dolomites

B2B SIGNED

Modeling spontaneous Breast cancer metastasis TO the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 B2B project word cloud

Explore the words cloud of the B2B project. It provides you a very rough idea of what is the project "B2B" about.

clinically    complexity    circulating    self    found    device    structure    dynamics    patient    spread    b2b    mortality    marrow    screening    breast    patients    woman    vitro    overcome    breakthrough    containing    date    drugs    bone    incurable    branched    barrier    context    pursue    cancer    organoids    technologies    physiological    composition    connected    ossicle    dimensions    identification    limitations    agents    transcend    recapitulate    hierarchical    first    cell    cells    vascular    lack    ossicles    nor    newly    therapies    fold    propagate    passing    capillary    dissect    tissue    bioprinted    hybrid    size    hits    spanning    hierarchically    consequently    longitudinally    continuum    comprising    tumor    million    networks    endothelial    macro    assembled    metastasis    disease    single    hurdle    circuit    empower    repurposing    site    3d    spontaneous    metastatic    ones    tree    model    micro    drug    throughput    vascularized    closed    linked    generate    suppressing   

Project "B2B" data sheet

The following table provides information about the project.

Coordinator
CONSIGLIO NAZIONALE DELLE RICERCHE 

Organization address
address: PIAZZALE ALDO MORO 7
city: ROMA
postcode: 185
website: www.cnr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.b2bproject.eu
 Total cost 3˙799˙371 €
 EC max contribution 3˙799˙371 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-1-2016-2017
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) coordinator 711˙887.00
2    UNIVERSITAT BASEL CH (BASEL) participant 1˙198˙345.00
3    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 464˙383.00
4    REACT4LIFE SRL IT (GENOVA) participant 406˙600.00
5    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 390˙825.00
6    CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED UK (CAMBRIDGE) participant 234˙242.00
7    IN SRL IT (UDINE) participant 230˙587.00
8    BIOEMISSION TECHNOLOGY SOLUTIONS IKE EL (ATHINA) participant 162˙500.00

Map

 Project objective

Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread of breast cancer cells to the bone. Consequently, metastasis-suppressing agents have not been found to date, neither as newly developed drugs nor as repurposing of existing ones. The aim of the B2B device is to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. B2B will pursue its goal of developing a novel hybrid device able to 1) propagate patient-derived tumor organoids of clinically-relevant dimensions, with their own self-assembled micro-capillary networks, which are 2) continuously linked to a 3D bioprinted macro-vascular tree, organized in a hierarchical branched structure, connected in a closed circuit with 3) a vascularized marrow-containing bone ossicle, as the metastatic target. This is a unique approach, spanning the micro (single circulating metastatic cells, passing the endothelial barrier of capillary networks) to macro (tumor organoids and ossicles of clinically relevant size and tissue composition, connected by a hierarchically organized vascular tree) continuum to recapitulate spontaneous bone metastasis formation in breast cancer. This technology will transcend the limitations of current in vitro technologies, enabling physiological tissue-level complexity with organoids comprising several million cells, and its expected impact will be three-fold: to recapitulate the spontaneous metastatic process in breast cancer, to provide a breakthrough technology to investigate metastasis longitudinally and at the single cell level, and to lead to the identification of metastasis-suppressing therapies for breast cancer patients.

 Deliverables

List of deliverables.
Website and logo Websites, patent fillings, videos etc. 2019-10-08 17:12:39

Take a look to the deliverables list in detail:  detailed list of B2B deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Francesc Castro-Giner, Sofia Gkountela, Cinzia Donato, Ilaria Alborelli, Luca Quagliata, Charlotte Ng, Salvatore Piscuoglio, Nicola Aceto
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
published pages: 31, ISSN: 2075-4418, DOI: 10.3390/diagnostics8020031
Diagnostics 8/2 2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "B2B" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "B2B" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FLIX (2020)

FLow chemistry for Isotopic eXchange

Read More  

EDRA (2019)

Hardware-Assisted Decoupled Access Execution on the Digital Market: The EDRA Framework

Read More  

cFLOW (2019)

Coherent ultraFast Long Wave infrared communications

Read More